OmniAb, Inc.

OmniAb is a biotechnology platform company that specializes in antibody discovery rather than drug commercialization. The company licenses its proprietary transgenic animal platforms—including OmniRat®, OmniChicken®, and OmniMouse®—to pharmaceutical and biotechnology partners to enable the discovery of next-generation therapeutic antibodies. Strategically operating as a life-science tools and intellectual-property company, OmniAb provides partners with access to diverse antibody repertoires and high-throughput screening technologies. The company generates revenue through upfront access fees, research milestones, and royalties on partnered programs that reach the market.